Treatments no longer in development for rheumatoid arthritis.
作者信息
Keystone E
机构信息
The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Canada.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii43-5. doi: 10.1136/ard.61.suppl_2.ii43.
Abstract
摘要
相似文献
1
Treatments no longer in development for rheumatoid arthritis.不再用于类风湿关节炎治疗研发的疗法。
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii43-5. doi: 10.1136/ard.61.suppl_2.ii43.
2
[Cytokines and anti-cytokine therapy in rheumatoid arthritis].
Internist (Berl). 2001 Jan;42(1):55-6, 59-63. doi: 10.1007/s001080050724.
3
[New treatments for rheumatoid arthritis].[类风湿关节炎的新疗法]
Soins. 2004 Sep(688):37-8.
4
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.使用肿瘤坏死因子α阻滞剂治疗类风湿性关节炎。
BMJ. 2002 Feb 9;324(7333):312-3. doi: 10.1136/bmj.324.7333.312.
5
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?当类风湿性关节炎患者对肿瘤坏死因子抑制剂治疗无效时：下一步该怎么做？
Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111.
6
Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.使用抗肿瘤坏死因子α治疗药物英夫利昔单抗治疗类风湿关节炎的临床试验综述。
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I61-4. doi: 10.1136/ard.58.2008.i61.
7
Tumor necrosis factor inhibitors for rheumatoid arthritis.用于类风湿关节炎的肿瘤坏死因子抑制剂。
N Engl J Med. 2006 Nov 9;355(19):2046-7; author reply 2048. doi: 10.1056/NEJMc062500.
8
Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.生物制剂单独及联合用于类风湿关节炎治疗的未来应用。
Z Rheumatol. 1998 Feb;57(1):41-5. doi: 10.1007/s003930050058.
9
[Experimental therapy of rheumatoid arthritis with antibodies to tumor necrosis factor].[用肿瘤坏死因子抗体对类风湿性关节炎进行实验性治疗]
Z Rheumatol. 1998 Oct;57(5):298-301. doi: 10.1007/s003930050115.
10
Adalimumab for rheumatoid arthritis.阿达木单抗用于治疗类风湿性关节炎。
Expert Opin Biol Ther. 2006 Dec;6(12):1349-60. doi: 10.1517/14712598.6.12.1349.
引用本文的文献
1
A large-scale Boolean model of the rheumatoid arthritis fibroblast-like synoviocytes predicts drug synergies in the arthritic joint.大规模布尔模型的类风湿关节炎成纤维样滑膜细胞预测药物协同作用在关节炎关节。
NPJ Syst Biol Appl. 2023 Jul 15;9(1):33. doi: 10.1038/s41540-023-00294-5.
2
Self-reactive T cells induce and perpetuate chronic relapsing arthritis.自身反应性 T 细胞诱导并维持慢性复发性关节炎。
Arthritis Res Ther. 2020 Apr 28;22(1):95. doi: 10.1186/s13075-020-2104-7.
3
MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.基质金属蛋白酶和解聚素金属蛋白酶在神经感染性疾病和多发性硬化中的作用。
Cell Mol Life Sci. 2019 Aug;76(16):3097-3116. doi: 10.1007/s00018-019-03174-6. Epub 2019 Jun 6.
4
Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.类风湿关节炎中表观遗传机制紊乱导致的基质金属蛋白酶基因激活
Int J Mol Sci. 2017 Apr 25;18(5):905. doi: 10.3390/ijms18050905.
5
Of mice and men: how animal models advance our understanding of T-cell function in RA.从鼠到人：动物模型如何促进我们对类风湿关节炎中T细胞功能的理解
Nat Rev Rheumatol. 2014 Mar;10(3):160-70. doi: 10.1038/nrrheum.2013.205. Epub 2014 Jan 7.
6
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?类风湿关节炎的发病机制：旧临床数据中的新见解？
Nat Rev Rheumatol. 2012 Mar 13;8(4):235-43. doi: 10.1038/nrrheum.2012.23.
7
Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis.类风湿关节炎滑液中效应记忆 CD8+T 细胞的特征。
J Clin Immunol. 2012 Aug;32(4):709-20. doi: 10.1007/s10875-012-9674-3. Epub 2012 Feb 25.
8
The Development of Novel Therapies for Rheumatoid Arthritis.类风湿关节炎新型疗法的进展
Expert Opin Ther Pat. 2008 Jul;18(7):723-738. doi: 10.1517/13543776.18.7.723.
9
Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway.迷迭香酸通过线粒体途径诱导类风湿性关节炎患者活化T细胞凋亡。
J Clin Immunol. 2007 Jan;27(1):36-45. doi: 10.1007/s10875-006-9057-8. Epub 2006 Dec 29.
本文引用的文献
1
2
Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis.白细胞介素-4与白细胞介素-10在类风湿关节炎炎症抑制及关节破坏中的协同作用
Arthritis Rheum. 2001 Jan;44(1):3-12. doi: 10.1002/1529-0131(200101)44:1<3::AID-ANR2>3.0.CO;2-U.
3
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.基质金属蛋白酶抑制作为一种新型抗癌策略：特别关注batimastat和marimastat的综述
Pharmacol Ther. 1997;75(1):69-75. doi: 10.1016/s0163-7258(97)00023-5.
4
Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.Ro 32 - 3555是一种口服活性胶原酶抑制剂，可在体内外防止软骨分解。
Br J Pharmacol. 1997 Jun;121(3):540-6. doi: 10.1038/sj.bjp.0701150.
5
Lambda light chain deposition disease presenting as sicca syndrome.
Arthritis Rheum. 1997 Mar;40(3):587-8. doi: 10.1002/art.1780400330.
6
Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience.
Arthritis Rheum. 1996 Nov;39(11):1773-80. doi: 10.1002/art.1780391102.
7
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
Arthritis Rheum. 1996 Jul;39(7):1102-8. doi: 10.1002/art.1780390705.
8
Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
Arthritis Rheum. 1996 Jan;39(1):52-6. doi: 10.1002/art.1780390107.
9
In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis.类风湿关节炎患者体内T细胞耗竭与体外IgM类风湿因子合成增加有关。
Clin Immunol Immunopathol. 1993 May;67(2):124-9. doi: 10.1006/clin.1993.1054.
10
A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
Arthritis Rheum. 1995 Aug;38(8):1097-106. doi: 10.1002/art.1780380812.
Zotero 插件